PrEP is a 16.265 Billion Worldwide Market, Rebecca Culshaw posts on PrEP, and UCLA's PrEPaganda
Fierce Pharma reports that the CDC patented PrEP in 2006 and that Gilead has created a $16.265 PrEP global market. This can buy a-lot of...
iPrex Study authors claim 45% efficacy of Truvada. The Press claims 90% or even 99%. Looking at the graph below, is this reasonable?
What study authors do not say in their NEJM article is they terminated their study early. It should have run 196 weeks or longer. The two lines appear to be converging - and in two other studies, they did converge. Had study authors not conveniently terminated their study when they could "p-hack" it, they would have told the truth: Truvada is 0% effective for pre-exposure prophylaxis.
Nucleoside Analogs are Toxic Irreversible Chemotherapy